Form 4 for PHR Phreesia, Inc.

Accepted 2024-09-10 00:00:00 ET · period of report 2024-09-06 · accession 0001127602-24-023716 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2024-09-10	2024-09-06	PHR	Linetsky David	SVP, Life Sciences	A - Grant	—	+234	9,187	+3%	—
	2024-09-10	2024-09-06	PHR	Linetsky David	SVP, Life Sciences	A - Grant	—	+2,816	205.0K	+1%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-09-06	A	A	234	—	9,187	I	—	—	(F2) Represents RSUs that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's spouse's cash bonus earned for the fiscal first half of the year ending January 31, 2025 under the Issuer's Variable Compensation Plan. The Reporting Person's spouse elected to convert such portion of her earned cash bonus into RSUs representing 115% of such amount. The number of RSUs granted is based on a per share value of $23.55, the closing price of the Issuer's common stock on September 6, 2024.
2	Common	Common Stock	2024-09-06	A	A	2,816	—	205,034	D By Spouse	—	—	(F1) Represents Restricted Stock Units ("RSUs") that were fully vested as of the grant date. These RSUs represent awards received in lieu of 50% of the Reporting Person's cash bonus earned for the first half of the fiscal year ending January 31, 2025 under the Issuer's Senior Executive Cash Incentive Bonus Plan. The Reporting Person elected to convert such portion of his cash bonus into RSUs representing 115% of the earned cash bonus amount. The number of RSUs granted is based on a per share value of $23.55, the closing price of the Issuer's common stock on September 6, 2024.